{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:03:46Z","timestamp":1777395826141,"version":"3.51.4"},"reference-count":40,"publisher":"SAGE Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,9,13]]},"abstract":"<jats:p>Background: Creutzfeldt-Jakob disease (CJD) can be difficult to distinguish clinically from some non-prion neurological diseases. Previous studies have reported markedly increased levels of \u03b1-synuclein in cerebrospinal fluid (CSF) of CJD patients, indicating that it is a potential diagnostic biomarker. Objective: The aim of this study was to assess the diagnostic power of CSF \u03b1-synuclein in discriminating CJD from non-prion disorders. Methods: The Ovid MEDLINE, Cochrane, and Embase databases were searched for articles published on or before February 25, 2022, using the search term (prion diseases OR Creutzfeldt-Jakob syndrome) AND (synuclein OR \u03b1-synuclein). The difference in CSF \u03b1-synuclein levels between CJD and non-prion diseases was calculated using random-effects models (I2\u200a&gt;\u200a50%) or fixed-effects models (I2\u200a&lt;\u200a50%) in terms of standardized mean difference (SMD) and 95% confidence interval (CI). The publication bias was estimated using funnel plots and the Egger\u2019s test. Results: Ten studies were included in this study. The concentrations of CSF \u03b1-synuclein were significantly higher in CJD patients compared to total non-prion controls (SMD\u200a=\u200a1.98, 95% CI 1.60 to 2.36, p\u200a&lt;\u200a0.00001), tauopathies (SMD\u200a=\u200a1.34, 95% CI 0.99 to 1.68, p\u200a&lt;\u200a0.00001), synucleinopathies (SMD\u200a=\u200a1.78, 95% CI 1.11 to 2.44, p\u200a&lt;\u200a0.00001), or Alzheimer\u2019s (SMD\u200a=\u200a1.14, 95% CI 0.95 to 1.33, p\u200a&lt;\u200a0.00001). CSF \u03b1-synuclein could distinguish CJD from non-prion diseases with overall sensitivity of 89% (95% CI 80\u201395%), specificity of 92% (95% CI 86\u201395%), and AUC of 0.96 (95% CI: 0.94\u20130.97). Conclusion: CSF \u03b1-synuclein has excellent diagnostic value in discriminating CJD from non-prion neurological diseases. Given the high heterogeneity among the included studies, further studies are needed to confirm its clinical utility.<\/jats:p>","DOI":"10.3233\/jad-220425","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T13:31:10Z","timestamp":1658842270000},"page":"493-503","source":"Crossref","is-referenced-by-count":7,"title":["Diagnostic Utility of Cerebrospinal Fluid \u03b1-Synuclein in Creutzfeldt-Jakob Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.1177","volume":"89","author":[{"given":"Yu","family":"Kong","sequence":"first","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Library, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjiao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Library, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-220425_ref1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneurol.2016.65","article-title":"Advanced tests for early and accurate diagnosis of Creutzfeldt-Jakob disease","volume":"12","author":"Zanusso","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-220425_ref2","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1007\/s00415-019-09537-0","article-title":"Diagnostic value of surrogate CSF biomarkers for Creutzfeldt-Jakob disease in the era of RT-QuIC","volume":"266","author":"Abu-Rumeileh","year":"2019","journal-title":"J Neurol"},{"key":"10.3233\/JAD-220425_ref3","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s12035-017-0479-5","article-title":"Validation of alpha-synuclein as a CSF biomarker for sporadic Creutzfeldt-Jakob disease","volume":"55","author":"Llorens","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-220425_ref4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jalz.2016.09.013","article-title":"Evaluation of \u03b1-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases","volume":"13","author":"Llorens","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220425_ref5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1749-6632.2000.tb06900.x","article-title":"The alpha-synucleinopathies: Parkinson\u2019s disease, dementia with Lewy bodies, and multiple system atrophy","volume":"920","author":"Spillantini","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.3233\/JAD-220425_ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00441-007-0565-5","article-title":"Cellular prion protein electron microscopy: Attempts\/limits and clues to a synaptic trait. implications in neurodegeneration process","volume":"332","author":"Fournier","year":"2008","journal-title":"Cell Tissue Res"},{"key":"10.3233\/JAD-220425_ref7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00001756-199301000-00017","article-title":"Synaptic degeneration is the primary neuropathological feature in prion disease: A preliminary study","volume":"4","author":"Clinton","year":"1993","journal-title":"Neuroreport"},{"key":"10.3233\/JAD-220425_ref8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1365-2990.2000.00216.x","article-title":"Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus","volume":"26","author":"Jeffrey","year":"2000","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.3233\/JAD-220425_ref9","doi-asserted-by":"crossref","first-page":"e12214","DOI":"10.1002\/dad2.12214","article-title":"Diagnostic and prognostic performance of CSF alpha-synuclein in prion disease in the context of rapidly progressive dementia","volume":"13","author":"Mastrangelo","year":"2021","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-220425_ref10","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00702-021-02443-8","article-title":"Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldt\u2013Jakob disease in clinical practice","volume":"129","author":"Fayolle","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JAD-220425_ref11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.dadm.2018.06.005","article-title":"Interlaboratory validation of cerebrospinal fluid \u03b1-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease","volume":"10","author":"Kruse","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.3233\/JAD-220425_ref12","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/ene.15258","article-title":"Diagnostic accuracy of cerebrospinal fluid biomarkers for the differential diagnosis of sporadic Creutzfeldt-Jakob disease: A (network) meta-analysis","volume":"29","author":"R\u00fcbsamen","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.3233\/JAD-220425_ref13","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1093\/brain\/awp191","article-title":"Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease","volume":"132","author":"Zerr","year":"2009","journal-title":"Brain"},{"key":"10.3233\/JAD-220425_ref15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(20)30477-4","article-title":"Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease","volume":"20","author":"Hermann","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220425_ref16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00401-012-1002-8","article-title":"Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: An inter-rater study among surveillance centres in Europe and USA","volume":"124","author":"Parchi","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-220425_ref17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.3233\/JAD-220425_ref18","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s00415-020-09870-9","article-title":"A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid \u03b2-amyloid42, total-tau, phospho-tau and \u03b1-synuclein in the differential diagnosis of neurodegenerative dementia","volume":"267","author":"Diaz-Lucena","year":"2020","journal-title":"J Neurol"},{"key":"10.3233\/JAD-220425_ref19","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s00415-015-7837-x","article-title":"Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD","volume":"262","author":"Llorens","year":"2015","journal-title":"J Neurol"},{"key":"10.3233\/JAD-220425_ref20","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1074\/mcp.M116.059915","article-title":"Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer\u2019s and Creutzfeldt-Jakob disease but no alteration in synucleinopathies","volume":"15","author":"Oeckl","year":"2016","journal-title":"Mol Cell Proteomics"},{"key":"10.3233\/JAD-220425_ref21","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1007\/s12035-018-1313-4","article-title":"Cerebrospinal fluid total and phosphorylated \u03b1-synuclein in patients with Creutzfeldt\u2013Jakob disease and synucleinopathy","volume":"56","author":"Schmitz","year":"2019","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-220425_ref22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","article-title":"Direct quantification of CSF \u03b1-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration","volume":"213","author":"Mollenhauer","year":"2008","journal-title":"Exp Neurol"},{"key":"10.3233\/JAD-220425_ref23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JAD-181152","article-title":"Cerebrospinal fluid and plasma biomarkers in neurodegenerative diseases","volume":"68","author":"Seino","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-220425_ref24","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","article-title":"\u03b1-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study","volume":"10","author":"Mollenhauer","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220425_ref25","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/mds.111","article-title":"\u03b1-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with Lewy bodies","volume":"33","author":"van Steenoven","year":"2018","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-220425_ref26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-5793(94)00395-5","article-title":"Identification of two distinct synucleins from human brain","volume":"345","author":"Jakes","year":"1994","journal-title":"FEBS Lett"},{"key":"10.3233\/JAD-220425_ref27","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","article-title":"Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal","volume":"8","author":"Maroteaux","year":"1988","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-220425_ref28","first-page":"1285","article-title":"Abnormal isoform of prion proteins accumulates in the synaptic structures of the central nervous system in patients with Creutzfeldt-Jakob disease","volume":"140","author":"Kitamoto","year":"1992","journal-title":"Am J Pathol"},{"key":"10.3233\/JAD-220425_ref29","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00415-014-7334-7","article-title":"Increased \u03b1-synuclein levels in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease","volume":"261","author":"Kasai","year":"2014","journal-title":"J Neurol"},{"key":"10.3233\/JAD-220425_ref30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1212\/01.WNL.0000078890.89473.ED","article-title":"14-3-3 protein in the CSF of patients with rapidly progressive dementia","volume":"61","author":"Huang","year":"2003","journal-title":"Neurology"},{"key":"10.3233\/JAD-220425_ref31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jalz.2015.10.009","article-title":"Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia","volume":"12","author":"Llorens","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-220425_ref32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","article-title":"Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort","volume":"78","author":"Schoonenboom","year":"2012","journal-title":"Neurology"},{"key":"10.3233\/JAD-220425_ref33","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/brain\/awab350","article-title":"Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases","volume":"145","author":"Schmitz","year":"2022","journal-title":"Brain"},{"key":"10.3233\/JAD-220425_ref34","doi-asserted-by":"crossref","first-page":"116605","DOI":"10.1016\/j.jns.2019.116605","article-title":"A case of M232R genetic Creutzfeldt-Jakob disease with Lewy bodies","volume":"409","author":"Akagi","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-220425_ref35","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1212\/01.WNL.0000033796.33205.B4","article-title":"A patient with dementia with Lewy bodies and codon 232 mutation of PRNP","volume":"59","author":"Koide","year":"2002","journal-title":"Neurology"},{"key":"10.3233\/JAD-220425_ref36","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00401-017-1755-1","article-title":"Alpha-synuclein oligomers: A new hope","volume":"134","author":"Bengoa-Vergniory","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-220425_ref37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(03)00481-2","article-title":"Soluble oligomers for the diagnosis of neurodegenerative diseases","volume":"2","author":"El-Agnaf","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-220425_ref38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13024-016-0072-9","article-title":"Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson\u2019s disease","volume":"11","author":"Majbour","year":"2016","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-220425_ref39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/jnc.14569","article-title":"Antibody-based methods for the measurement of \u03b1-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study","volume":"149","author":"Mollenhauer","year":"2019","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-220425_ref40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/bmm.12.46","article-title":"Recommendations to standardize preanalytical confounding factors in Alzheimer\u2019s and Parkinson\u2019s disease cerebrospinal fluid biomarkers: An update","volume":"6","author":"del Campo","year":"2012","journal-title":"Biomark Med"},{"key":"10.3233\/JAD-220425_ref41","doi-asserted-by":"crossref","first-page":"638718","DOI":"10.3389\/fnagi.2021.638718","article-title":"Preanalytical stability of CSF total and oligomeric alpha-synuclein","volume":"13","author":"Abdi","year":"2021","journal-title":"Front Aging Neurosci"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-220425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:06:50Z","timestamp":1777370810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-220425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":40,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jad-220425","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]}}}